The deal may be completed in months. Integrating the products can take years.
MedTech is consolidating.
After one of the strongest years for dealmaking in a decade, PwC reported that MedTech M&A remained active in the first half of 2026, with approximately $36.5 billion in disclosed deal value.
The strategic logic is clear.
Acquire innovation.
Enter faster-growing categories.
Add new technologies.
Build broader portfolios.
Strengthen positions within hospitals and healthcare systems.
Accelerate growth.
But once the bankers, lawyers and corporate development teams have completed the transaction, somebody inherits a much more complicated problem.
The products.
Suddenly there may be two product portfolios.
Two design languages.
Two technology platforms.
Two software environments.
Two sets of user interfaces.
Two development roadmaps.
Two sets of suppliers.
And quite possibly two completely different philosophies about how products should be developed.
The acquisition may have created value on a spreadsheet.
The challenge for product teams is turning that theoretical value into something customers can actually see, use and buy.
The acquisition is only the beginning
M&A has become an increasingly important part of the MedTech growth model.
PwC describes M&A as a critical component of the sector’s growth algorithm, particularly as companies seek differentiated technologies, category leadership and access to higher-growth markets.
McKinsey makes a similar observation. Large MedTech companies increasingly source innovative products from smaller organisations and then use their commercial infrastructure to scale them.
But buying innovation and integrating innovation are very different capabilities.
That distinction matters.
Because poorly considered integration can destroy exactly what made the acquired business attractive in the first place.
The acquiring company naturally wants efficiency.
Shared platforms.
Common components.
Consolidated suppliers.
Unified software.
Consistent design.
Fewer SKUs.
Lower manufacturing costs.
Those objectives can all be sensible.
But pursued too aggressively, harmonisation can become homogenisation.
And the product that differentiated the acquired company gradually disappears into the corporate machine.
Product integration is not a cosmetic exercise
One of the most dangerous assumptions following an acquisition is that product harmonisation means making everything look the same.
Change the colours.
Apply the corporate brand.
Standardise the interface.
Update the packaging.
Job done.
It isn’t.
True portfolio integration goes much deeper.
It asks whether products should share components, technologies, digital architecture, interaction principles and manufacturing processes.
It looks at where duplication exists.
It identifies which technologies should become platforms.
It determines which products should remain distinct.
It challenges which legacy products should survive at all.
And critically, it considers how all of this affects the customer.
A portfolio may make perfect sense internally while appearing completely incoherent to the clinician using it.
That is why the starting point should not be:
How do we make these products look like they belong together?
It should be:
What should the combined portfolio become?
The duplication problem
Acquisitions frequently create product overlap.
Two devices may solve essentially the same problem.
Two development teams may be working on similar technologies.
Different products may contain components performing identical functions.
Separate software teams may be developing parallel capabilities.
McKinsey has documented precisely this problem within medical devices. In one case, an acquisition left two business units producing essentially the same product. Rationalising the portfolio required bringing the R&D teams together, redesigning overlapping products and reconsidering how products were designed and sourced.
That is where integration can become an opportunity rather than simply an operational burden.
Because the objective does not have to be choosing Product A or Product B.
Sometimes the right answer is Product C.
Take the strongest elements of both.
Challenge the assumptions behind them.
Remove unnecessary complexity.
Standardise what customers do not value.
Differentiate what they do.
And create something better than either organisation had before the acquisition.
Harmonise the invisible. Differentiate the valuable.
This is where portfolio integration becomes strategically interesting.
Not everything should be standardised.
But not everything should remain unique either.
The skill is knowing the difference.
A common internal architecture might reduce development and manufacturing complexity across several products.
Shared components could simplify procurement and supply chains.
A common interaction framework could reduce training requirements.
A unified digital platform could allow previously separate products to exchange information.
Shared design principles could make the portfolio easier for customers to understand.
But none of those decisions should be made simply because standardisation is possible.
The question should always be:
Does this create value?
For the business.
For the development team.
For manufacturing.
For the healthcare professional.
And ultimately for the patient.
The strongest portfolio strategy therefore combines two apparently opposing objectives:
Standardise aggressively behind the product. Differentiate intelligently in front of the customer.
Don’t integrate yesterday’s products
There is another trap.
Integration programmes naturally focus on what already exists.
How do we combine these portfolios?
How do we consolidate these platforms?
How do we rationalise these SKUs?
But a major acquisition creates a rare opportunity to ask a more valuable question:
If we were designing this portfolio today, would we design it this way?
Often the answer is no.
Technologies have changed.
Clinical workflows have changed.
Digital expectations have changed.
Manufacturing technologies have changed.
AI is changing what products can do.
Customers may be using devices differently.
And both organisations may be carrying years of legacy decisions.
Simply combining two historic portfolios can therefore create one larger historic portfolio.
The more ambitious approach is to use the acquisition as a catalyst for redesign.
Integration needs speed
This is where large organisations face an inherent challenge.
McKinsey has highlighted how MedTech companies can trade speed and proximity to customers for centralisation, while cross-functional changes can take months or even years to align across portfolio management, R&D, commercial, manufacturing and supply chain functions.
Acquisitions add another layer of complexity.
More stakeholders.
More governance.
More competing priorities.
More history.
Meanwhile, the market keeps moving.
That creates a strong case for a different development model.
A small, senior, multidisciplinary team.
Protected from unnecessary organisational complexity.
Given a clearly defined challenge.
Able to work across industrial design, engineering, UX/UI and human factors.
Connected directly to decision makers.
And expected to build, test and demonstrate possibilities quickly.
Rather than attempting to solve the entire integration programme at once, such a team can attack specific high-value questions.
What could a common product architecture look like?
Can these two platforms become one?
Which elements should be standardised?
Where should differentiation remain?
Could a shared UI reduce training?
What should the next-generation product look like?
Can we demonstrate it?
The objective is not another strategy presentation.
It is evidence.
Build the answer
At Maddison, we believe integration decisions become much easier when organisations can see and experience the alternatives.
So build them.
Create alternative architectures.
Prototype interfaces.
Explore physical product families.
Map user journeys.
Put concepts in front of clinicians.
Test whether assumptions survive contact with reality.
Then iterate.
A prototype can resolve an argument that might otherwise occupy months of meetings.
This is particularly powerful following an acquisition because internal teams inevitably bring history with them.
The acquired team understandably wants to protect what it built.
The acquiring organisation understandably wants to leverage its existing capabilities.
Neither perspective is necessarily wrong.
But both can constrain thinking.
An independent product team can start somewhere different:
What creates the strongest product and portfolio for the future?
That is the role Maddison can play.
Working alongside internal R&D, engineering and commercial teams, we can rapidly investigate difficult integration challenges without becoming another layer of the integration structure.
Small team.
Clear problem.
Rapid development.
Tangible answers.
M&A should create better products, not just bigger companies
The current wave of MedTech consolidation is unlikely to be temporary.
PwC expects strategic buyers to continue pursuing innovation, higher-growth adjacencies, connected care and broader healthcare ecosystems. EY similarly argues that value creation increasingly depends on sustained innovation combined with strategically executed M&A.
That means product integration is becoming a core MedTech capability.
The companies that do it well will not simply acquire technologies.
They will combine capabilities.
Simplify portfolios.
Create stronger platforms.
Accelerate innovation.
And build products that neither organisation could have created independently.
Because ultimately, the success of a MedTech acquisition should not only be measured by the deal value, cost synergies or portfolio size.
It should be visible in what comes next.
Better products.
Better experiences.
Better platforms.
And a stronger innovation pipeline than either company had before.
That is when acquisition becomes transformation.
References
- PwC, Medtech: US Deals 2026 Midyear Outlook, June 2026.
- EY, Pulse of the MedTech Industry Report, 2025.
- McKinsey & Company, Talent, Tech, and Team: The Formula for MedTech R&D Success, July 2025.
- McKinsey & Company, Transforming MedTech Operating Models, 2025.
- McKinsey & Company, Delivering Growth: M&A in Medical Technology.
- McKinsey & Company, Designing Products for Value.